IL6 and juvenile idiopathic arthritis: Targeting IL-6 pathway seems so promising in JIA that another antibody targeting IL-6R, sarilumab, is in phase II trials for polyarticular JIA and systemic JIA (ClinicalTrialsGov NCT02776735; NCT02991469).